OakChart

ADARx Pharmaceuticals Inc

ADRXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

13.30-0.27 (-1.99%)
2026-11-11 22:27 CET
Market cap
1,504.03 USD m
Revenue, TTM
0.75 USD m
Net income, TTM
-25.76 USD m
Free cash flow, TTM
-27.56 USD m
EPS diluted, TTM
-0.24
P/E
-
Compare

Price

ADRX against its 20-day averages
20
12.5015.0017.5020.0022.502.1M4.2MVolumeSep 26Oct 26Nov 26ADRXclose 13.3020-day 16.2913.3052w high52w low

42.7% under the 52-week high of 23.21 on 25 Sep 2026. 52-week low 12.50 on 6 Nov 2026. Last 15 sessions, 52.6% high to low

Volume 0.79× normal · the line is the 50-bar volume average

Profile

ADRX
52-week range, 7% of the way up
12.5023.21

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

IPOSep 25, 2026
ATR, 14d1.47
Rel volume0.79
Short float3.97%
Insider own59.08%
Inst own1.52%

Snapshot

6 groups

Valuation

Index-
Market Cap1.47B
Enterprise Value1.41B
Income-
Sales-
Book/sh-2.35
Cash/sh3.85
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOSep 25, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C3.45
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio12.98
Current Ratio12.98
Debt/Eq0.06
LT Debt/Eq0.05
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.82
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.- -

Ownership

Insider Own59.08%
Insider Trans8.56%
Inst Own1.52%
Inst Trans15.66%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-18.36%
SMA50-23.04%
SMA200-23.04%
Trades-

Technical

Shs Outstand106.80M
Shs Float45.36M
Short Float3.97%
Short Ratio2.79
Short Interest1.80M
52W High23.21 -42.70%
52W Low12.50 6.40%
Volatility12.18% 8.43%
ATR (14)1.47
RSI (14)25.93
Beta-
Rel Volume0.79
Avg Volume645.24K
Volume509,953

Performance

Perf Week-11.10%
Perf Month-24.86%
Perf Quarter-
Perf Half Y-
Perf YTD-39.82%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price34.25
Prev Close13.57
Price13.30
Change %-1.99%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Oct 20, 2026InitiatedUUBSBuy$35+163.2%
Oct 20, 2026InitiatedTTD CowenBuy
Oct 20, 2026InitiatedMMorgan StanleyOverweight$32+140.6%
Oct 20, 2026InitiatedJJP MorganOverweight$38+185.7%

Peers

Mkt cap
TickerCompanyMkt cap
ARWRArrowhead Pharmaceuticals Inc6.97B
ALNYAlnylam Pharmaceuticals Inc21.41B
IONSIonis Pharmaceuticals Inc4.71B
WVEWave Life Sciences Inc674.52M
ABUSArbutus Biopharma Corp768.65M
DYNDyne Therapeutics Inc3.37B
STOKStoke Therapeutics Inc1.81B
SLNSilence Therapeutics Plc ADR1.23B
VKTXViking Therapeutics Inc3.62B
RNAAtrium Therapeutics Inc177.32M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Chimovits ErezDirectorSep 28 '26Buy17.0061,5161,045,7729,292,025Sep 30 05:29 PM
GORDON CARL LDirectorSep 28 '26Buy17.00950,00016,150,00014,325,529Sep 30 05:25 PM
ORBIMED ADVISORS LLCDirectorSep 28 '26Buy17.00950,00016,150,00014,325,529Sep 30 05:23 PM
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerSep 28 '26Buy17.001,600,00027,200,0005,554,094Sep 29 09:45 PM
George SimeonDirectorSep 28 '26Buy17.001,600,00027,200,0005,554,094Sep 29 09:43 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
TMEDT. Rowe Price Health Care ETFAUM: 38.55M
TDNAT. Rowe Price Biotech ETFAUM: 11.46M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
TSEET. Rowe Price Small Cap ETFAUM: 10.79M
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-2.467--2.4670.87--
2026Q3---0.822--2.584
2026Q4---0.371--2.584
2027Q1---0.380--0.003
2027Q2---0.423--0.003
2027Q3---0.373--0.003
2027Q4---0.397--0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-193002.580.007.00
2026Q3R2026-10-19300-0.92-2.20-0.25
2026Q3E2026-10-20400-0.82-2.20-0.25
2026Q3E2026-10-19300-0.92-2.20-0.25

Estimate history

EPS, annual-0.434-0.684
Period20242025
EPS, quarterly-0.146-0.169-0.212-0.241
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Sales, annual03.449
Period20242025
Sales, quarterly00.2082.140.746
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Shares, annual106.801106.801106.801
Period20242025MRQ
Shares, quarterly106.801106.801106.801106.801
PeriodQ1 '25Q2 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.753.450.00
Cost of Goods Sold Incl. D&A0.732.331.50
Gross Profit0.011.12-1.50
Selling, General and Administrative Excl. Other29.9089.4956.73
Research and Development24.7471.5143.36
Other Operating Expense0.000.000.00
Operating Income-29.89-88.36-58.23
Interest Expense0.000.000.00
Unusual Expense0.000.000.00
Net Income Before Taxes-25.76-73.09-46.36
Income Taxes0.000.000.00
Consolidated Net Income-25.76-73.09-46.36
Net Income From Continuing Operations-25.76-73.09-46.36
Net Income-25.76-73.09-46.36
EPS (Recurring)-0.24-0.68-0.43
EPS (Basic, Before Extraordinaries)-0.24-0.68-0.43
EPS (Diluted)-0.24-0.68-0.43
EBITDA-29.16-86.04-56.73
Non-Operating Income (Expense)4.1315.2811.87
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense1.516.133.95
Gross Margin-32.53-
Operating Margin--2,562.05-
Net Margin--2,119.11-
Shares Outstanding106.80106.80106.80
Market Capitalization1,504.031,504.03-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Total Revenue0.752.140.210.00
Cost of Goods Sold Incl. D&A0.730.720.630.51
Gross Profit0.011.42-0.42-0.51
Selling, General and Administrative Excl. Other29.9028.4820.7017.37
Research and Development24.7423.5817.0712.89
Other Operating Expense0.000.000.000.00
Operating Income-29.89-27.06-21.12-17.89
Interest Expense0.000.000.000.00
Unusual Expense0.000.000.000.00
Net Income Before Taxes-25.76-22.67-18.09-15.55
Income Taxes0.000.000.000.00
Consolidated Net Income-25.76-22.67-18.09-15.55
Net Income From Continuing Operations-25.76-22.67-18.09-15.55
Net Income-25.76-22.67-18.09-15.55
EPS (Recurring)-0.24-0.21-0.17-0.15
EPS (Basic, Before Extraordinaries)-0.24-0.21-0.17-0.15
EPS (Diluted)-0.24-0.21-0.17-0.15
EBITDA-29.16-26.34-20.50-17.37
Non-Operating Income (Expense)4.134.393.032.34
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense1.510.841.151.73
Gross Margin1.4766.36-200.96-
Operating Margin-4,006.84-1,264.30-10,154.81-
Net Margin-3,452.95-1,059.21-8,698.56-
Shares Outstanding106.80106.80106.80106.80
Market Capitalization1,504.03---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments480.00219.48
Short Term Receivables0.000.00
Inventories0.000.00
Other Current Assets13.386.19
Total Current Assets493.38225.67
Net Property, Plant & Equipment12.077.13
Total Investments and Advances0.000.00
Other Assets2.210.66
Total Assets507.65233.45
Short Term Debt Incl. Current Port. of LT Debt1.710.79
Accounts Payable5.841.35
Other Current Liabilities22.936.80
Total Current Liabilities30.488.94
Long Term Debt6.033.54
Provision for Risks Charges0.000.00
Other Liabilities315.770.51
Total Liabilities352.2912.98
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value357.62357.62
Common Equity-202.25-137.15
Total Shareholders Equity155.37220.48
Accumulated Minority Interest0.000.00
Total Equity155.37220.48
Total Liabilities & Stockholders Equity507.65233.45
Book Value Per Share-1.89-1.28
Tangible Book Value Per Share-1.89-1.28
Price to Book Ratio-5.77-
Return on Assets-19.72-
Return on Equity-38.89-
Return on Invested Capital-45.29-20.70
Quick Ratio16.1825.25
Current Ratio16.1825.25

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-25.76-73.09-46.36
Depreciation0.732.331.50
Other Funds (Non Cash)1.433.24-3.14
Funds from Operations-23.60-67.52-48.00
Extraordinary Item0.000.000.00
Changes in Working Capital-3.59329.81-0.56
Cash from Operating Activities-27.19262.29-48.56
Capital Expenditures-0.37-2.94-0.46
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments22.13-206.9939.97
Purchase of Investments-16.87-403.49-181.03
Sale Or Maturity of Investments39.00196.50221.00
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities21.76-209.9339.51
Cash Dividends Paid0.000.000.00
Change in Capital Stock0.010.100.23
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock0.010.100.23
Proceedsfrom Stock Options0.000.000.00
Issuance or Reduction of Debt, Net0.000.000.00
Change in Long Term Debt0.000.000.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities0.010.100.23
Exchange Rate Effect0.050.020.01
Net Change in Cash-5.3752.48-8.82
Free Cash Flow-27.56259.35-49.02
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Cash & Short Term Investments427.25455.82--
Short Term Receivables0.000.00--
Inventories0.000.00--
Other Current Assets14.2912.90--
Total Current Assets441.54468.72--
Net Property, Plant & Equipment10.9811.60--
Total Investments and Advances0.000.00--
Other Assets3.812.24--
Total Assets456.33482.56--
Short Term Debt Incl. Current Port. of LT Debt1.711.71--
Accounts Payable4.866.77--
Other Current Liabilities27.4421.27--
Total Current Liabilities34.0129.75--
Long Term Debt5.195.62--
Provision for Risks Charges0.000.00--
Other Liabilities310.56315.30--
Total Liabilities349.76350.67--
Non-Equity Reserves0.000.00--
Preferred Stock - Carrying Value357.62357.62--
Common Equity-251.05-225.73--
Total Shareholders Equity106.57131.89--
Accumulated Minority Interest0.000.00--
Total Equity106.57131.89--
Total Liabilities & Stockholders Equity456.33482.56--
Book Value Per Share-2.35-2.11--
Tangible Book Value Per Share-2.35-2.11--
Full-Time Employees100103--
Price to Book Ratio-5.77---
Return on Invested Capital-23.05-16.48--
Quick Ratio12.9815.75--
Current Ratio12.9815.75--

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Net Income-25.76-22.67-18.09-15.55
Depreciation0.730.720.630.51
Other Funds (Non Cash)1.430.630.380.69
Funds from Operations-23.60-21.32-17.09-14.34
Extraordinary Item0.000.000.000.00
Changes in Working Capital-3.59-1.36330.531.64
Cash from Operating Activities-27.19-22.68313.44-12.71
Capital Expenditures-0.37-0.08-0.99-0.50
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments22.1320.04-262.1714.44
Purchase of Investments-16.87-24.96-308.17-39.56
Sale Or Maturity of Investments39.0045.0046.0054.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities21.7619.96-263.1713.94
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.00
Change in Capital Stock0.010.000.080.00
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock0.010.000.080.00
Proceedsfrom Stock Options0.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities0.010.000.080.00
Exchange Rate Effect0.050.060.02-0.01
Net Change in Cash-5.37-2.6650.381.23
Free Cash Flow-27.56-22.76312.45-13.20

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.97%1.8M45.4M703.51K
2026-10-154.20%1.9M45.4M953.63K
2026-09-306.43%1.2M18.1M1.88M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-16SCHEDULE 13GSEC
2026-10-05SCHEDULE 13DSEC
2026-10-02SCHEDULE 13DSEC
2026-10-01SCHEDULE 13GSEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-28S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-28424B4SEC
2026-09-24EFFECTEffectiveness filing by commission orderSEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-24CERTSEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0987.75M500
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC3.41%
Aberdeen Group plc0.11%
Laurion Capital Management LP0.02%
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.0.01%
UBS Group AG0.00%

Funds

Fund% owned
-

OakChart. ADRX. Cached 15 minutes.

Some panels did not load: news.